The Journal of Urology
Volume 178, Issue 5 , Pages 1883-1887 , November 2007

Sunitinib Efficacy Against Advanced Renal Cell Carcinoma

  • Robert J. Motzer

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • Corresponding Author InformationCorrespondence: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, New York 10021.
    • Financial interest and/or other relationship with Pfizer.
    • ,
  • M. Dror Michaelson

      Affiliations

    • Massachusetts General Hospital, Boston, Massachusetts
    • Financial interest and/or other relationship with Pfizer and Wyeth Research.
    • ,
  • Jonathan Rosenberg

      Affiliations

    • University of California-San Francisco, San Francisco, California
    • Financial interest and/or other relationship with Pfizer.
    • ,
  • Ronald M. Bukowski

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • Financial interest and/or other relationship with Pfizer, Bayer, Genentech, Wyeth and Novartis.
    • ,
  • Brendan D. Curti

      Affiliations

    • Earle A. Chiles Research Institute, Portland, Oregon
    • ,
  • Daniel J. George

      Affiliations

    • Duke University Medical Center, Durham, North Carolina
    • Financial interest and/or other relationship with Pfizer.
    • ,
  • Gary R. Hudes

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, Pennsylvania
    • Financial interest and/or other relationship with Pfizer and Wyeth Research.
    • ,
  • Bruce G. Redman

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • Kim A. Margolin

      Affiliations

    • City of Hope National Medical Center, Duarte, California
    • ,
  • George Wilding

      Affiliations

    • University of Wisconsin, Madison, Wisconsin

Received 14 March 2007

References 

  1. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408
  2. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454
  3. Linehan WM, Vasselli J, Srinivasan R, McClellan MW, Merino M, Choyke P, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282S
  4. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991
  5. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327
  6. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16
  7. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516
  8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205
  9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115
  10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289
  11. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 1999;18:1928
  12. Hudes GR, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol. 2006;24:930s
  13. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427
  14. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125
  15. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81
  16. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal cell cancer. N Engl J Med. 2001;345:1655
  17. Mickisch GH, Garin AM, vanPoppel H, dePrick L, Sylvestor R. Tumor nephrectomy plus interferon alpha is superior to interferon alpha alone in metastatic renal cell carcinoma. Lancet. 2001;358:966
  18. Rini BI, Shaw V, Rosenberg JE, Kim S, Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer. 2006;5:232

 Study received approval from the institution review board at each participating center.

 Supported by Pfizer, Inc.

PII: S0022-5347(07)01766-1

doi: 10.1016/j.juro.2007.07.030

The Journal of Urology
Volume 178, Issue 5 , Pages 1883-1887 , November 2007

Article Tools

* Image Usage & Resolution